Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

News Briefs

EU Expands Indication for Gilead HIV Drug

May 28, 2003

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

On Tuesday, Gilead Science announced it has received authorization from the European Union to expand the indication of its HIV drug Viread in all 15 EU states. With the expansion, Viread is approved for use in combination with other drugs to prevent the duplication of HIV in patients initiating antiretroviral therapy as well as in previously treated patients. The EU's Committee for Proprietary Medicinal Products and the Scientific Committee of the European Medicines Evaluation Agency gave the marketing authorization based on a 49-week study of 600 treatment-naive HIV-infected patients, Gilead said.

Back to other CDC news for May 28, 2003

Previous Updates

Adapted from:
Reuters
05.27.03

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More News on HIV/AIDS in Western Europe

Tools
 

Advertisement